These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 620612)

  • 1. Pharmacodynamic interference between rifampicin and isoniazid.
    Llorens J; Serrano RJ; Sanchez R
    Chemotherapy; 1978; 24(2):97-103. PubMed ID: 620612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of different oral doses of isoniazid-rifampicin in rats.
    Rana SV; Pal R; Vaiphie K; Singh K
    Mol Cell Biochem; 2006 Sep; 289(1-2):39-47. PubMed ID: 16583132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and safety evaluation of the use of ciprofloxacin on an isoniazid-rifampicin regimen in rabbits.
    Padilha EC; Pires RV; Filho MA; de Pontes Machado DV; Baldan HM; Davanço MG; Campos ML; Brunetti IL; Peccinini RG
    Biopharm Drug Dispos; 2012 Dec; 33(9):501-9. PubMed ID: 23007681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological study of rifampicin after repeated high dosage during intermittent combined therapy. II. Bilirubin levels and other biochemical determinations.
    Verbist L; Rollier F
    Respiration; 1971; 28():Suppl:17-28. PubMed ID: 5150793
    [No Abstract]   [Full Text] [Related]  

  • 5. The Australian rifampicin trial.
    Proust AJ
    Med J Aust; 1971 Jul; 2(2):85-94. PubMed ID: 4999365
    [No Abstract]   [Full Text] [Related]  

  • 6. [The influence of rifampicin upon the metabolism of isoniazid (author's transl)].
    Modai J; Coulaud JP; Vivien JM; Berthelot G; Bergogne-Berezin E
    Nouv Presse Med; 1978 Apr; 7(15):1263-7. PubMed ID: 662655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury.
    Wang C; Fan RQ; Zhang YX; Nie H; Li K
    World J Gastroenterol; 2016 Nov; 22(44):9775-9783. PubMed ID: 27956801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats.
    Naji KM; Al-Khatib BY; Al-Haj NS; D'souza MR
    BMC Pharmacol Toxicol; 2021 Jul; 22(1):39. PubMed ID: 34217369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatoprotective effect of Anacyclus pyrethrum Linn. against antitubercular drug-induced hepatotoxicity in SD rats.
    Usmani A; Mujahid M; Khushtar M; Siddiqui HH; Rahman MA
    J Complement Integr Med; 2016 Sep; 13(3):295-300. PubMed ID: 27101559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Liver toxicity of combined rifampicin-isoniazid-ethambutol medication (author's transl)].
    Austerhoff A; Kindler U; Knop P; Knieriem HJ
    Dtsch Med Wochenschr; 1974 May; 99(22):1182 p. PubMed ID: 4835559
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatoprotective effect of lawsone on rifampicin-isoniazid induced hepatotoxicity in in vitro and in vivo models.
    Darvin SS; Esakkimuthu S; Toppo E; Balakrishna K; Paulraj MG; Pandikumar P; Ignacimuthu S; Al-Dhabi NA
    Environ Toxicol Pharmacol; 2018 Jul; 61():87-94. PubMed ID: 29859372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reparation of Isoniazid and Rifampicin Combinatorial Therapy-Induced Hepatotoxic Effects by Bacopa monnieri.
    Evan Prince S; Udhaya LB; Sunitha PS; Arumugam G
    Pharmacology; 2016; 98(1-2):29-34. PubMed ID: 27007136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.
    Acocella G; Bonollo L; Garimoldi M; Mainardi M; Tenconi LT; Nicolis FB
    Gut; 1972 Jan; 13(1):47-53. PubMed ID: 5060669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.
    Scharer L; Smith JP
    Ann Intern Med; 1969 Dec; 71(6):1113-20. PubMed ID: 5361410
    [No Abstract]   [Full Text] [Related]  

  • 15. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.
    Guo YX; Xu XF; Zhang QZ; Li C; Deng Y; Jiang P; He LY; Peng WX
    Toxicol Mech Methods; 2015; 25(5):382-7. PubMed ID: 25886055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative characterization of the hepatotoxicity of isoniazid, rifampicin and pyrazinamide].
    Slivka IuI
    Farmakol Toksikol; 1989; 52(4):82-5. PubMed ID: 2806536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A metabolic and kinetic study on the association rifampicin-isoniazid.
    Acocella G
    Respiration; 1971; 28():Suppl:1-6. PubMed ID: 4948628
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rimactan (rifampicin) and anticoagulant therapy].
    Michot F; Bürgi M; Büttner J
    Schweiz Med Wochenschr; 1970 Mar; 100(13):583-4. PubMed ID: 5420855
    [No Abstract]   [Full Text] [Related]  

  • 19. [Frequency, diagnosis, and course of hepatotoxic side effects of Rifampicin (author's transl)].
    Deck KA; Gehrhardt A; Klein HO; Ludes H
    Med Klin; 1976 Oct; 71(43):1836-41. PubMed ID: 995024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
    Grönhagen-Riska C; Hellstrom PE; Fröseth B
    Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.